NCT00382200: A trial that was reported late by Memorial Sloan Kettering Cancer Center
This trial has reported, although it was 27 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT00382200 |
|---|---|
| Title | Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 31, 2006 |
| Completion date | Jan. 5, 2023 |
| Required reporting date | Jan. 5, 2024, midnight |
| Actual reporting date | Feb. 1, 2024 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 27 |